Jason S. Rush
Broad Institute
5 Papers
Jason S. Rush is an academic researcher from Broad Institute. The author has contributed to research in topics: Ubiquitin & Biology. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal Immunity and Intestinal Inflammation
Zhifang Cao,Kara L. Conway,Kara L. Conway,Robert J. Heath,Robert J. Heath,Jason S. Rush,Elizaveta S. Leshchiner,Zaida G. Ramirez-Ortiz,Natalia B. Nedelsky,Hailiang Huang,Hailiang Huang,Aylwin Ng,Aylwin Ng,Agnes Gardet,Shih-Chin Cheng,Alykhan F. Shamji,John D. Rioux,Cisca Wijmenga,Mihai G. Netea,Terry K. Means,Mark J. Daly,Mark J. Daly,Ramnik J. Xavier,Ramnik J. Xavier +23 more
TL;DR: It was shown that the protective variant of CARD9, which is C-terminally truncated, acted in a dominant-negative manner for CARD9-mediated cytokine production, indicating an important role for the C terminus in CARD9 signaling.
125
RNF166 Determines Recruitment of Adaptor Proteins during Antibacterial Autophagy
Robert J. Heath,Robert J. Heath,Gautam Goel,Gautam Goel,Leigh A. Baxt,Leigh A. Baxt,Jason S. Rush,Vishnu Mohanan,Vishnu Mohanan,Geraldine L.C. Paulus,Geraldine L.C. Paulus,Vijay Jani,Vijay Jani,Kara G. Lassen,Kara G. Lassen,Ramnik J. Xavier,Ramnik J. Xavier +16 more
TL;DR: In this article, the role of E3 ligases in antibacterial autophagy has been investigated and it was shown that RNF166 catalyzes K29-and K33-linked polyubiquitination of p62 at residues K91 and K189.
87
Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease
Elizaveta S. Leshchiner,Elizaveta S. Leshchiner,Jason S. Rush,Michael A. Durney,Zhifang Cao,Zhifang Cao,Vlado Dančík,Benjamin Chittick,Huixian Wu,Adam Petrone,Joshua A. Bittker,Andrew J. Phillips,José Carlos Rodríguez Pérez,Alykhan F. Shamji,Virendar K. Kaushik,Mark J. Daly,Mark J. Daly,Daniel B. Graham,Daniel B. Graham,Stuart L. Schreiber,Stuart L. Schreiber,Ramnik J. Xavier,Ramnik J. Xavier +22 more
TL;DR: The feasibility of using small-molecule inhibitors to recapitulate the antiinflammatory function of CARD9 mutations associated with protection from IBD is demonstrated and biochemical insights into CARD9 variant proteins are used to create a blueprint for IBD therapeutics.
52
USP15 Deubiquitinates CARD9 to Downregulate C-Type Lectin Receptor-Mediated Signaling.
Wenting Xu,Wenting Xu,Jason S. Rush,Daniel B. Graham,Daniel B. Graham,Zhifang Cao,Zhifang Cao,Ramnik J. Xavier,Ramnik J. Xavier +8 more
- 01 Oct 2020
TL;DR: The USP15 knockdown and knockout specifically enhance CARD9-dependent CLR signaling in both mouse and human immune cells and provides a blueprint for the identification of additional deubiquitinases that are likely to control these processes.
7
Patent
Compositions and methods for treating inflammatory bowel disease
Elizaveta S. Leshchiner,Zhifang Cao,Jason S. Rush,Michael A. Durney,Alykhan F. Shamji,Daniel B. Graham,Stuart L. Schreiber,Ramnik J. Xavier +7 more
- 04 Apr 2019
TL;DR: In this paper, compounds for the treatment of inflammatory bowel disease were described and compositions and methods for using these compounds and compositions in the treatment in a subject with inflammatory bowel diseases were described.